Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib
Language English Country Greece Media print
Document type Journal Article
PubMed
25503188
PII: 34/12/7461
Knihovny.cz E-resources
- Keywords
- Hyponatremia, NSCLC, OS, PFS, predictive marker, prognosis,
- MeSH
- Quinazolines therapeutic use MeSH
- Adult MeSH
- ErbB Receptors antagonists & inhibitors MeSH
- Erlotinib Hydrochloride MeSH
- Hyponatremia blood diagnosis MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Biomarkers, Tumor blood MeSH
- Lung Neoplasms blood drug therapy mortality MeSH
- Carcinoma, Non-Small-Cell Lung blood drug therapy mortality MeSH
- Disease-Free Survival MeSH
- Proportional Hazards Models MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Sodium blood MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Quinazolines MeSH
- ErbB Receptors MeSH
- Erlotinib Hydrochloride MeSH
- Protein Kinase Inhibitors MeSH
- Biomarkers, Tumor MeSH
- Sodium MeSH
BACKGROUND: Hyponatremia is a well-known phenomenon in cancer patients. The aim of our retrospective study was to assess the relationship of natremia levels to predict treatment with erlotinib and also to assess the prognosis of patients with hyponatremia. PATIENTS AND METODS: We analyzed data of 544 patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. RESULTS: Hyponatremia was measured in 21.5 % of patients before treatment with erlotinib. We found a significant increase in the effectiveness of treatment with erlotinib in patients with normal levels of sodium to hyponatremic patients. Progression-free survival (PFS) and overall survival (OS) were also significantly higher in patients with normal natremia. Multivariate Cox model analysis demonstrated that natremia was an independent factor for PFS and OS. CONSLUSION: We reported hyponatremia not only as a prognostic marker in NSCLC patients but also as predictive marker of erlotinib treatment efficacy, being an independent factor at the present large retrospective study. Its possible effect in clinical practice is bigger thanks the simple possibility of testing of hyponatremia and the low cost of this biomarker.
Centre for Applied Genomics of Solid Tumours Genomac Research Institute Prague Czech Republic
Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic
